Pharmaceutical Executive
July 01, 2012
Issue PDF
0
0
2012 Emerging Pharma Leaders
July 01, 2012
Features
0
0
Meet the rest of 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history?
July 01, 2012
Column
0
0
Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. Jill Wechsler reports.
July 01, 2012
From the Editor
0
0
Pharm Exec's 2012 roster of Emerging Leaders-our sixth to date-is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.
July 01, 2012
Column
0
0
Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation.
July 01, 2012
Features
0
0
Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded-and lengthy-race to registration.
July 01, 2012
Features
0
0
In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises-change for pharma is here and its good.
July 01, 2012
Column
0
0
At its core, pharma marketing is about conversations. Dynamic, persuasive conversations between companies and healthcare stakeholders. But one time it was simple; now it's not, writes Al Topin.